Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Similar articles for PubMed (Select 10942046)

1.

Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease.

Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque EX.

Behav Brain Res. 2000 Aug;113(1-2):199-206. Review.

PMID:
10942046
2.

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease.

Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, Zerlin M.

Biol Psychiatry. 2001 Feb 1;49(3):279-88. Review.

PMID:
11230879
3.

Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.

Maelicke A, Albuquerque EX.

Eur J Pharmacol. 2000 Mar 30;393(1-3):165-70.

PMID:
10771010
4.

Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.

Samochocki M, Höffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lübbert H, Albuquerque EX, Maelicke A.

J Pharmacol Exp Ther. 2003 Jun;305(3):1024-36. Epub 2003 Mar 20.

5.

Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.

Maelicke A.

Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:11-8. Review.

PMID:
10971047
6.

The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system.

Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A, Albuquerque EX.

Mol Pharmacol. 2002 May;61(5):1222-34.

8.

In vitro galantamine-memantine co-application: mechanism of beneficial action.

Zhao X, Marszalec W, Toth PT, Huang J, Yeh JZ, Narahashi T.

Neuropharmacology. 2006 Dec;51(7-8):1181-91. Epub 2006 Sep 29.

PMID:
17011596
9.

Physostigmine, galanthamine and codeine act as 'noncompetitive nicotinic receptor agonists' on clonal rat pheochromocytoma cells.

Storch A, Schrattenholz A, Cooper JC, Abdel Ghani EM, Gutbrod O, Weber KH, Reinhardt S, Lobron C, Hermsen B, Soskiç V, et al.

Eur J Pharmacol. 1995 Aug 15;290(3):207-19.

PMID:
7589215
10.

Structural model for the binding sites of allosterically potentiating ligands on nicotinic acetylcholine receptors.

Luttmann E, Ludwig J, Höffle-Maas A, Samochocki M, Maelicke A, Fels G.

ChemMedChem. 2009 Nov;4(11):1874-82. doi: 10.1002/cmdc.200900320.

PMID:
19739198
11.

Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease.

Albuquerque EX, Santos MD, Alkondon M, Pereira EF, Maelicke A.

Alzheimer Dis Assoc Disord. 2001 Aug;15 Suppl 1:S19-25.

PMID:
11669505
12.

Potential applications of nicotinic ligands in the laboratory and clinic.

Dani JA, De Biasi M, Liang Y, Peterson J, Zhang L, Zhang T, Zhou FM.

Bioorg Med Chem Lett. 2004 Apr 19;14(8):1837-9. Review.

PMID:
15050611
13.

Impaired muscarinic regulation of excitatory synaptic transmission in the APPswe/PS1dE9 mouse model of Alzheimer's disease.

Goto Y, Niidome T, Hongo H, Akaike A, Kihara T, Sugimoto H.

Eur J Pharmacol. 2008 Mar 31;583(1):84-91. doi: 10.1016/j.ejphar.2008.01.030. Epub 2008 Feb 5.

PMID:
18282567
14.

Allosteric modulation of Torpedo nicotinic acetylcholine receptor ion channel activity by noncompetitive agonists.

Maelicke A, Coban T, Storch A, Schrattenholz A, Pereira EF, Albuquerque EX.

J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):11-28.

PMID:
9029479
15.

Nicotinic cholinergic modulation: galantamine as a prototype.

Woodruff-Pak DS, Lander C, Geerts H.

CNS Drug Rev. 2002 Winter;8(4):405-26. Review.

PMID:
12481195
16.

Unique mechanism of action of Alzheimer's drugs on brain nicotinic acetylcholine receptors and NMDA receptors.

Narahashi T, Marszalec W, Moriguchi S, Yeh JZ, Zhao X.

Life Sci. 2003 Dec 5;74(2-3):281-91.

PMID:
14607256
17.

Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands.

Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, Maelicke A.

Mol Pharmacol. 1996 Jan;49(1):1-6.

PMID:
8569694
18.

Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-thiazolemethanol (JNJ-1930942), a novel positive allosteric modulator of the {alpha}7 nicotinic acetylcholine receptor.

Dinklo T, Shaban H, Thuring JW, Lavreysen H, Stevens KE, Zheng L, Mackie C, Grantham C, Vandenberk I, Meulders G, Peeters L, Verachtert H, De Prins E, Lesage AS.

J Pharmacol Exp Ther. 2011 Feb;336(2):560-74. doi: 10.1124/jpet.110.173245. Epub 2010 Nov 17.

20.

Physostigmine and acetylcholine differentially activate nicotinic receptor subpopulations in Locusta migratoria neurons.

van den Beukel I, van Kleef RG, Zwart R, Oortgiesen M.

Brain Res. 1998 Apr 13;789(2):263-73.

PMID:
9573380
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk